Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03165487 · ClinicalTrials.gov registry record
Comparison of the Breast Tumor Microenvironment
A clinical trial of Triple Negative Breast Cancer and Hormone Receptor Positive Malignant Neoplasm of Breast, sponsored by Columbia University.
- Active
- Registry status
- 14
- Enrollment target
- 1
- Study location
NCT03165487 is a study of Triple Negative Breast Cancer and Hormone Receptor Positive Malignant Neoplasm of Breast that is active but no longer recruiting, run by Columbia University. The registered enrollment target is 14 participants, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03165487, a study of Triple Negative Breast Cancer and Hormone Receptor Positive Malignant Neoplasm of Breast, is active but no longer recruiting, sponsored by Columbia University.
- ACTIVE NOT RECRUITING
- Registry status
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the project is to identify a molecular signature of tumor stroma from "normal" adjacent breast tissue obtained prospectively at the time of breast conserving surgery before and after receiving intraoperative radiation therapy (IORT) in subjects that have luminal A and triple negative breast cancer. IORT is considered as being standard of care.
Conditions Studied
Interventions
- OTHER Blood sample collection
- OTHER Breast tissue collection
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2017-09-28 |
| Est. Completion | 2027-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03165487
The ClinicalTrials.gov registry entry for NCT03165487 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Triple Negative Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Blood sample collection is the first listed.
NCT03165487 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03165487 about?
NCT03165487 is a clinical study titled "Comparison of the Breast Tumor Microenvironment". The goal of the project is to identify a molecular signature of tumor stroma from "normal" adjacent breast tissue obtained prospectively at the time of breast conserving surgery before and after receiving intraoperative radiation therapy (IORT) in subjects that have luminal A and triple negative bre...
What is the current status of trial NCT03165487?
This trial is currently active not recruiting. The enrollment target is 14 participants. The study started on 2017-09-28. Estimated completion is 2027-12-01.
What conditions does trial NCT03165487 study?
This clinical trial studies the following conditions: Triple Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast.
What interventions are being tested in trial NCT03165487?
The interventions under investigation include: Blood sample collection (OTHER), Breast tissue collection (OTHER).
Who is sponsoring clinical trial NCT03165487?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03165487 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Triple Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients
RECRUITING · Phase 2
-
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Triple Negative Breast Cancer
All registered trials for this condition
Hormone Receptor Positive Malignant Neoplasm of Breast
All registered trials for this condition
New York
All trials with a study site in New York
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.